PTPN22 R620W minor allele is a genetic risk factor for giant cell arteritis by Lester, Susan et al.
SHORT REPORT
PTPN22 R620W minor allele is a genetic
risk factor for giant cell arteritis
Susan Lester,1,2 Alex W Hewitt,3 Carlee D Ruediger,1,2 Linda Bradbury,4,5
Elisabeth De Smit,6 Michael D Wiese,7 Rachel Black,1 Andrew Harrison,8
Graeme Jones,9 Geoffrey O Littlejohn,10 Tony R Merriman,11 Bain Shenstone,12
Malcolm D Smith,13 Maureen Rischmueller,1,2 Matthew A Brown,4,5
Catherine L Hill1,2,14
To cite: Lester S, Hewitt AW,
Ruediger CD, et al. PTPN22
R620W minor allele is a
genetic risk factor for giant
cell arteritis. RMD Open
2016;2:e000246.
doi:10.1136/rmdopen-2016-
000246
▸ Prepublication history
and additional material is
available. To view please visit
the journal (http://dx.doi.org/
10.1136/rmdopen-2016-
000246).
Received 10 January 2016
Revised 3 March 2016
Accepted 8 March 2016
For numbered affiliations see
end of article.
Correspondence to
Susan Lester;
susan.lester@sa.gov.au
ABSTRACT
Giant cell arteritis (GCA) is one of the commonest
forms of vasculitis in the elderly, and may result in
blindness and stroke. The pathogenesis of GCA is not
understood, although environmental, infectious and
genetic risk factors are implicated. One gene of interest
is PTPN22, encoding lymphoid protein tyrosine
phosphatase (Lyp), expressed exclusively in immune
cells, which is proposed to be an ‘archetypal non-HLA
autoimmunity gene’. The minor allele of a functional
PTPN22 single nucleotide polymorphism (rs2476601,
R620W), which disrupts an interaction motif in the
protein, was originally reported to be associated with
biopsy-proven GCA in Spanish patients, with
supporting data from three replicate Northern European
studies. Recently, this observation was extended with
additional patients and controls, and studies
encompassing European, Scandinavian, UK and
American patients. The aim of our study was to
determine the association between PTPN22 rs2476601
(R620W) and biopsy-proven GCA in an Australian case
cohort.
Giant cell arteritis (GCA) is one of the
commonest forms of vasculitis in the elderly,
and may result in blindness and stroke.1 The
pathogenesis of GCA is not understood,
although environmental, infectious and
genetic risk factors are implicated. One gene
of interest is PTPN22, encoding lymphoid
protein tyrosine phosphatase (Lyp),
expressed exclusively in immune cells, which
is proposed to be an ‘archetypal non-HLA
autoimmunity gene’.2 3 The minor allele of a
functional PTPN22 single nucleotide poly-
morphism (rs2476601, R620W), which dis-
rupts an interaction motif in the protein, was
originally reported to be associated with
biopsy-proven GCA in Spanish patients, with
supporting data from three replicate
Northern European studies.4 Recently, this
observation was extended with additional
patients and controls, and studies encom-
passing European, Scandinavian, UK and
American patients.5 The aim of our study
was to determine the association between
PTPN22 rs2476601 (R620W) and biopsy-
proven GCA in an Australian case cohort.
Australian patients with biopsy-proven
GCA were recruited through the Arthritis
Genomics Recruitment Initiative in
Australasia (AGRIA), and the study consisted
of 209 patients with biopsy-proven GCA and
455 South Australian European-ancestry
population-based controls. The mean age of
the patients with biopsy-proven GCA was
73 years, 66% were female, 70% presented
with temporal headache, 1% with scalp ten-
derness, 54% with jaw claudication, 31% with
visual disturbance, 4% with stroke and 40%
with concurrent polymyalgia rheumatica.
rs2476601 Genotyping was performed
using a Taqman allelic discrimination assay
(C-16021387) on a Viia7 Real-Time PCR
System (Applied Biosystems, Foster City,
California, USA). A random-effects
meta-analysis, based on the allele frequencies
from all cohorts,5 was performed using the R
library metafor.6
Key messages
▸ PTPN22 may be an archetypal autoimmunity
gene.
▸ In this study we have estimated the frequency of
the PTPN22 rs2476601 (R620W) variant in
Australian Giant Cell Arteritis (GCA) patients of
European ancestry compared to population
based controls.
▸ Meta-analysis of all available studies from popu-
lations of both Northern and Southern European
ancestry, confirm an association between the
rs2476601 minor allele variant and GCA.
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rs2476601 Genotypes and allele frequencies for
Australian patients with GCA and controls are reported
in table 1. The genotypes of the control population were
in Hardy-Weinberg equilibrium (p=0.19). Although not
reaching statistical signiﬁcance, there was a trend
towards an excess of minor (A) allele homozygosity
within patients with GCA (p=0.09). There was a small
increase in the minor (A) allele frequency in patients
with GCA (OR 1.15, 95% CI 0.76 to 1.72), but this did
not reach statistical signiﬁcance (p=0.51)
The meta-analysis of rs2476601 minor allele frequen-
cies from all available GCA case–control studies is
reported in ﬁgure 1. The effect size from our Australian
study is in keeping with the ﬁndings from other studies
of patients with Northern European ancestry. While the
majority of these GCA studies, including ours, were
underpowered to detect an association, the results from
each study are remarkably consistent and collectively
indicate a signiﬁcant association between the rs2476601
minor allele and GCA (OR 1.33, 95% CI 1.16 to 1.52,
p=3×10−5).
Although not quite reaching statistical signiﬁcance,
there was also a trend towards larger effect sizes for
studies involving Southern European ancestry partici-
pants (p=0.054). In this context, it is interesting that the
risk of GCA, which is highest in Northern European
populations (about 20 cases per 100 000 persons older
than 50 years) and lower in Southern European popula-
tions (about 10 cases per 100 000),7 parallels a similar
North-South cline in rs2476601 minor allele frequencies
across Europe.3 Therefore, it is possible that PTPN22
rs2476601 minor allele contributes more to GCA risk on
a non-Northern European genetic background, or alter-
natively, that GCA cases from Southern Europe have
more Northern European ancestry than population-
matched controls.
A limitation of this study is that the most appropriate
genetic association model was not determined because
full genotype information was only available for the
Australian data. Interestingly, using the Australian data,
the Akaike information criterion (AIC) suggested that
the recessive association model (AIC 826.1) was slightly
better than either the additive (AIC 830.7) or dominant
models (AIC 831.1). However, given that only ﬁve minor
allele homozygotes were observed in a total of 664 parti-
cipants, there was insufﬁcient information to determine
the most appropriate model.
In summary, there is a signiﬁcant association between
the minor allele of PTPN22 rs2476601 and GCA,
although the pathogenic mechanism remains to be elu-
cidated. Power is a limiting factor in GCA genetic associ-
ation studies due to difﬁculties in recruitment of elderly
patients. However, this example illustrates the value of
data from multiple, yet small, studies in delivering robust
ﬁndings.
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Table 1 Genotype distribution and minor (A) allele frequency of PTPN22 rs2476601 in Australian patients with giant cell
arteritis (GCA) and controls
Genotype Minor allele (A)
Group n GG AG AA Frequency Minor allele OR (95% CI) p Value
Control 455 381 73 1 0.082 1
GCA 209 174 31 4 0.093 1.15 (0.76 to 1.72) 0.51
Figure 1 Random-effects (RE) meta-analysis of PTPN22
rs2476601 minor (A) allele frequencies in patients with giant
cell arteritis (GCA) (n=1860) compared to controls (n=15 761).
Data from the current Australian study was combined with
previously reported case–control studies.5 Results between
the studies were consistent: τ2 was estimated as 0.0034 (on
the log scale), and there was no substantive heterogeneity
(Q=4.72, df=6, p=0.58). The difference in effect sizes between
Northern and Southern European ancestry studies did not
reach statistical significance (p=0.054).
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